相关实验视频

Updated: Sep 12, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

作为抗癌剂的CD44向的N-甲二化诺衍生物具有较高的瘤对正常细胞选择性

Soledad Romero-Tamudo¹, M Dora Carrión², Meriem Chayah³

¹Department of Medicinal and Organic Chemistry and Excellence Research Unit of Chemistry Applied to Biomedicine and the Environment, Faculty of Pharmacy, University of Granada, Campus Cartuja s/n, 18071, Granada, Spain; GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Avda. Ilustración 114, 18016, Granada, Spain; Instituto de Investigación Biosanitaria ibs.GRANADA, 18012, Granada, Spain.

European journal of medicinal chemistry

|August 8, 2025

概括

新的四化素 (THIQ) 衍生物显示出作为向癌症治疗的前景. SRT5和SRT6抑制CD44相互作用,而SRT1在肺癌细胞中表现出强大的抗增殖作用,具有良好的选择性和药理动力学.

科学领域:

药用化学医学化学
癌症生物学癌症生物学
分子药理学分子药理学

背景情况:

细胞表面糖蛋白CD44与癌症的进展有关,使其成为小分子治疗的目标.
之前的研究已经确定了四化素 (THIQ) 衍生物的抗癌潜力.

研究的目的:

设计,合成和评估新型N-基THIQ衍生物 (SRT2-SRT10) 作为潜在的针对CD44.4的抗癌剂.
在乳腺和肺癌模型中研究这些化合物的作用机制和选择性.

主要方法:

一系列N-甲THIQ类似物的合成.
试验室试验包括结合试验,细胞活力研究和亡诱导.
分子动力学模拟用于预测药物向相互作用.
激酶分析和ADME预测.

主要成果:

在乳腺癌细胞中,SRT5和SRT6有效抑制了氨酸-CD44相互作用.
在CD44+肺癌细胞系中,SRT1表现出强大的抗增殖活性 (A549,NCI-H23).
SRT5和SRT6抑制了CD44相关的激酶 (例如SRC),而SRT1则通过激酶独立的途径起作用.
所有化合物都对癌细胞具有高选择性,而非瘤肺细胞具有有利的ADME预测.

结论:

N-基THIQ衍生物,特别是SRT1,SRT5和SRT6,显示出作为向肺癌治疗的选择性剂的显著潜力.
观察到不同的作用机制,突出显示了这种化学支架的多功能性.
进一步的体内验证和机理学研究是有必要的,以推动这些化合物进入临床应用.

关键词:

它具有抗增殖效果的作用.差异化的集群 44 44 氨酸是什么? 氨酸是什么?分子动力学模拟的模拟.四化化素的含量是多少

更多相关视频

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Published on: November 11, 2021

Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics

Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics

Published on: May 11, 2016

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...